{"id":20491,"date":"2023-10-27T09:11:25","date_gmt":"2023-10-27T09:11:25","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20491"},"modified":"2023-10-27T09:11:25","modified_gmt":"2023-10-27T09:11:25","slug":"mogrify-raises-46m-to-advance-reprogramming-therapies","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/mogrify-raises-46m-to-advance-reprogramming-therapies\/","title":{"rendered":"Mogrify raises $46m to advance reprogramming therapies"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Mogrify raises $46m to advance reprogramming therapies<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify\u2019s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.<\/h3>\n

<\/p>\n

This additional close was co-led by strategic corporate investor, Astellas Venture Management and Parkwalk Advisors, the leading funder of UK university spin-outs, with support from Ahren Innovation Capital, Trend Investment Group, and Dr Jonathan Milner, co-founder of Abcam.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Proceeds from the financing will be used to advance Mogrify\u2019s pipeline of in vivo reprogramming therapies, delivering the milestones necessary to facilitate a Series B fundraise in 2024\/25 and subsequent progression of a lead programme into first-in-human studies. The company\u2019s pipeline aims to address degenerative diseases of the eye, ear and pancreas via direct in vivo restoration of clinically valuable cell types.<\/p>\n

Mogrify\u2019s proprietary platform technologies enable systematic identification of the key transcriptomic and epigenetic cell switches required to control human cell fate. Deploying next-generation sequencing and a human gene regulatory network-centric approach, the platforms uniquely position the company to affect direct in vivo transdifferentiation between any source cell type and any target cell type of clinical interest.<\/p>\n<\/div><\/section>
\n